论文部分内容阅读
美国FDA批准Viberzi(eluxadoline)与Xifaxan(利福昔明),用于治疗成年患者的腹泻型肠易激综合征(IBS-D)。据美国国立卫生研究院提供的信息,肠易激综合征(IBS)患者会发生多种体征与症状,包括腹部疼痛或不适及肠排便变化。而IBS-D是该疾病的一种亚型,其主要特征是至少25%的时间出现稀便或水样便。Viberzi中含有一种新的活性成分,随食物每天服用2次,可激活神经系统中的受体,减少肠的收缩。Xifaxan可每天服用3次,连续服用14天,用于治疗IBS-D患者的腹痛与腹泻。经历症状复发的
The US FDA approved Viberzi (eluxadoline) and Xifaxan (rifaximin) for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D) in adult patients. According to information provided by the National Institutes of Health, patients with irritable bowel syndrome (IBS) develop various signs and symptoms, including abdominal pain or discomfort and intestinal defecation. While IBS-D is a subtype of the disease, its main characteristic is loose stools or watery stools for at least 25% of the time. Viberzi contains a new active ingredient, taken with food twice daily, can activate the receptors in the nervous system, reducing intestinal contraction. Xifaxan can be taken 3 times a day for 14 consecutive days to treat abdominal pain and diarrhea in patients with IBS-D. Experiencing symptoms of recurrence